Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Time to Achieve Platelet Count Response after Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: A Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)

Catherine M. Broome, Vickie McDonald, Yoshitaka Miyakawa, Monica Carpenedo, David J Kuter, Hanny Al-Samkari, James B. Bussel, Anna Hultberg, Filip Matthijssens, Jaume Ayguasanosa, Kristof De Beuf, Francesco Rodeghiero, Marc Michel, Adrian Newland

Blood (2023) 142 (Supplement 1): 689.

https://doi.org/10.1182/blood-2023-189125

Published: 2023

Journal Articles

Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: Results of a Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)

Catherine M. Broome, Vickie McDonald, Yoshitaka Miyakawa, Monica Carpenedo, David J. Kuter, Hanny Al-Samkari, James B. Bussel, Marie Godar, Jaume Ayguasanosa, Kristof De Beuf, Francesco Rodeghiero, Marc Michel, Adrian C. Newland

Blood (2022) 140 (Supplement 1): 6–8.

https://doi.org/10.1182/blood-2022-167838

Published: 2022

Journal Articles

Pharmacokinetic / Pharmacodynamic (PK/PD) Simulations Guide Selection of the Dose for Administration of Efgartigimod Subcutaneously in a Phase 3 Clinical Trial in Patients with Primary Immune Thrombocytopenia

Waleed Ghanima, Vickie McDonald, Shivi Jain, Monica Carpenedo, Esther N. Oliva, Anna Hultberg, Domenica Gandini, Erik Hofman, Tonke Van Bragt, Wim Parys, Benjamin van Hoorick, Yoshitaka Miyakawa, Catherine M. Broome

Blood (2021) 138 (Supplement 1): 3165.

https://doi.org/10.1182/blood-2021-153261

Published: 2021

Journal Articles

Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia

Blood (2021) 138 (7): 571–583.

https://doi.org/10.1182/blood.2021010735

Published: 2021

Includes: Supplemental data

Journal Articles

A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia

Blood (2020) 136 (2): 171–182.

https://doi.org/10.1182/blood.2019004596

Published: 2020

Includes: Supplemental data

Journal Articles

Clinical and Morphologic Predictors of Outcome in a Multicenter Cohort of ITP Patients Treated with Trombopoietin Analogues

Bruno Fattizzo, MD, Raffaella Pasquale, Monica Carpenedo, Silvia Cantoni, Giuseppe Auteri, MD, Doriana Gramegna, MD, Mariella D'adda, MD, Mariasanta Napolitano, Marco Ruggeri, MD, Sergio Siragusa, MD Professor, Giuseppe Rossi, Nicola Vianelli, MD, Wilma Barcellini, MD

Blood (2018) 132 (Supplement 1): 3764.

https://doi.org/10.1182/blood-2018-99-116627

Published: 2018

Journal Articles

Real-Life Management of Immune Thrombocytopenia in the Elderly: A Multicentre Study on 526 Patients

Blood (2018) 132 (Supplement 1): 2433.

https://doi.org/10.1182/blood-2018-99-114586

Published: 2018

Journal Articles

Combined Elevated Anti-Adamts-13 Antibody Level and Low Adamts-13 Activity during Remission Highly Predicts Disease Relapse in a Prospective Cohort of Patients with Autoimmune Thrombotic Thrombocytopenic Purpura (TTP)

Francesca Schieppati, MD, Laura Russo, Marina Marchetti, Gloria Caldara, Shenaz Brevi, Maria Testa, Luca Barcella, Monica Carpenedo, Mariella D'Adda, Giuseppe Rossi, Chiara Savignano, Atto Billio, Massimiliano Bruno Franco, Vincenzo Toschi, Anna Falanga

Blood (2018) 132 (Supplement 1): 2443.

https://doi.org/10.1182/blood-2018-99-119317

Published: 2018

Journal Articles

The Transition from Childhood to Adulthood in Chronic Immune Thrombocytopenia Patients: Clinical Management and the Role of Splenectomy and Thrombopoietin Receptor Agonists in a Single Center Experience

Monica Carpenedo, MD, Marco Spinelli, MD, Sara Pezzatti, MD, Momcilo Jancovic, MD, Rossella Renso, MD, Andrea Biondi, Carlo Gambacorti-Passerini, MD

Blood (2018) 132 (Supplement 1): 4987.

https://doi.org/10.1182/blood-2018-99-114050

Published: 2018

Journal Articles

Eltrombopag As Second Line Therapy in Adult Patients with Primary Immune Thrombocytopenia (ITP) in Attempt to Achieve Long-Term Remission. Preliminary Analysis of a Phase II, Multicenter, Prospective Study By Gimema Group (the ESTIT Study)

Blood (2018) 132 (Supplement 1): 1135.

https://doi.org/10.1182/blood-2018-99-113314

Published: 2018

Journal Articles

Clinical relevance of antiplatelet antibodies and the hepatic clearance of platelets in patients with immune thrombocytopenia

Silvia Cantoni, Monica Carpenedo, Michele Nichelatti, Lanfranco Sica, Silvano Rossini, Massimo Milella, Cristina Popescu, Roberto Cairoli

Blood (2016) 128 (17): 2183–2185.

https://doi.org/10.1182/blood-2016-03-708388

Published: 2016

Journal Articles

Is Ashwell-Morell Receptor Mediated Hepatic Clearance of Platelet Clinically Relevant in Immune Thrombocytopenia (ITP)? a Retrospective Analysis of Platelet Kinetic Studies and Autoantibody Type Data

Silvia Cantoni, MD, Monica Carpenedo, MD, Domenico Sica Lanfranco, MD, Michele Nichelatti, Massimo Milella, MD, Angela Centroni, MD, Roberto Cairoli, MD

Blood (2015) 126 (23): 2248.

https://doi.org/10.1182/blood.V126.23.2248.2248

Published: 2015

Journal Articles

Thrombopoietin Receptor Agonist (TPO-RA) Switch in Adult Primary Immune Thrombocytopenia (ITP) Patients: A Retrospective Collaborative Survey from 8 Italian Hematology Centers

Silvia Cantoni, MD, Monica Carpenedo, MD, Maria Gabriella Mazzucconi, MD, Valerio De Stefano, MD, Marco Ruggeri, MD, Nicola Vianelli, MD, Francesco Zaja, Wilma Barcellini, MD, Michele Nichelatti, Veronica Coccini, MD, Erminia Baldacci, Elena Rossi, MD, Simona Puglisi, Angela Ciminello, MD, Roberto Cairoli, MD

Blood (2015) 126 (23): 3462.

https://doi.org/10.1182/blood.V126.23.3462.3462

Published: 2015

Journal Articles

Health-Related Quality of Life in Patients with Primary Immune Thrombocytopenia (pITP): Investigating Differences Amongst Newly Diagnosed, Persistent and Chronic Pitp Patients

Blood (2015) 126 (23): 2122.

https://doi.org/10.1182/blood.V126.23.2122.2122

Published: 2015

Journal Articles

Predictors of Outcome and Response to Therapy in Primary Autoimmune Hemolytic Anemia: A Gimema Study of 307 Patients

Blood (2014) 124 (21): 1346.

https://doi.org/10.1182/blood.V124.21.1346.1346

Published: 2014

Journal Articles

Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients

Blood (2014) 124 (19): 2930–2936.

https://doi.org/10.1182/blood-2014-06-583021

Published: 2014

Includes: Supplemental data

Journal Articles

Platelet Cut-Off For Anticoagulant Therapy In Cancer Patients With Venous Thromboembolism and Thrombocytopenia: An Expert Opinion Based On RAND/UCLA Appropriateness Method (RAM)

Giorgia Saccullo, MD, Marco Marietta, Monica Carpenedo, Valerio De Stefano, MD, Anna Falanga, Augusto B. Federici, MD, Francesco Rodeghiero, Alberto Tosetto, M.D., Sergio Siragusa, MD

Blood (2013) 122 (21): 581.

https://doi.org/10.1182/blood.V122.21.581.581

Published: 2013

Journal Articles

Health-Related Quality of Life in Patients with Primary Immune Thrombocytopenia Compared with the General Population

Fabio Efficace, Paola Fazi, Francesco Rodeghiero, MD, Gianluca Gaidano, MD, PhD, Piercarla Schinco, Monica Carpenedo, Alessandro Rambaldi, MD, Maria Pina Simula, Paolo De Fabritiis, Paolo Ditonno, Giovanni Caocci, MD, Salvatore Soldati, Alessandra Borchiellini, Erminia Baldacci, Julia Daragjati, Franco Mandelli, MD, Maria Gabriella Mazzucconi

Blood (2012) 120 (21): 2056.

https://doi.org/10.1182/blood.V120.21.2056.2056

Published: 2012

NARROW

Time to Achieve Platelet Count Response after Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: A Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)

Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: Results of a Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)

Pharmacokinetic / Pharmacodynamic (PK/PD) Simulations Guide Selection of the Dose for Administration of Efgartigimod Subcutaneously in a Phase 3 Clinical Trial in Patients with Primary Immune Thrombocytopenia

Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia

A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia

Clinical and Morphologic Predictors of Outcome in a Multicenter Cohort of ITP Patients Treated with Trombopoietin Analogues

Real-Life Management of Immune Thrombocytopenia in the Elderly: A Multicentre Study on 526 Patients

Combined Elevated Anti-Adamts-13 Antibody Level and Low Adamts-13 Activity during Remission Highly Predicts Disease Relapse in a Prospective Cohort of Patients with Autoimmune Thrombotic Thrombocytopenic Purpura (TTP)

The Transition from Childhood to Adulthood in Chronic Immune Thrombocytopenia Patients: Clinical Management and the Role of Splenectomy and Thrombopoietin Receptor Agonists in a Single Center Experience

Eltrombopag As Second Line Therapy in Adult Patients with Primary Immune Thrombocytopenia (ITP) in Attempt to Achieve Long-Term Remission. Preliminary Analysis of a Phase II, Multicenter, Prospective Study By Gimema Group (the ESTIT Study)

Clinical relevance of antiplatelet antibodies and the hepatic clearance of platelets in patients with immune thrombocytopenia

Is Ashwell-Morell Receptor Mediated Hepatic Clearance of Platelet Clinically Relevant in Immune Thrombocytopenia (ITP)? a Retrospective Analysis of Platelet Kinetic Studies and Autoantibody Type Data

Thrombopoietin Receptor Agonist (TPO-RA) Switch in Adult Primary Immune Thrombocytopenia (ITP) Patients: A Retrospective Collaborative Survey from 8 Italian Hematology Centers

Health-Related Quality of Life in Patients with Primary Immune Thrombocytopenia (pITP): Investigating Differences Amongst Newly Diagnosed, Persistent and Chronic Pitp Patients

Predictors of Outcome and Response to Therapy in Primary Autoimmune Hemolytic Anemia: A Gimema Study of 307 Patients

Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients

Platelet Cut-Off For Anticoagulant Therapy In Cancer Patients With Venous Thromboembolism and Thrombocytopenia: An Expert Opinion Based On RAND/UCLA Appropriateness Method (RAM)

Health-Related Quality of Life in Patients with Primary Immune Thrombocytopenia Compared with the General Population

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only